We rank companies based on fund manager, research analyst and news sentiment
AVRO stock icon

AVROBIO
AVRO

$1.26
0.79%
 

About: Avrobio Inc is a clinical-stage gene therapy company. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.

Employees: 13

0
Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

17,657% more call options, than puts

Call options by funds: $169K | Put options by funds: $952

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

5.02% less ownership

Funds ownership: 58.15% [Q3] → 53.14% (-5.02%) [Q4]

8% less funds holding

Funds holding: 48 [Q3] → 44 (-4) [Q4]

19% less capital invested

Capital invested by funds: $39.9M [Q3] → $32.2M (-$7.67M) [Q4]

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$2
59%
upside
Avg. target
$2
59%
upside
High target
$2
59%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Mizuho
Uy Ear
59%upside
$2
Neutral
Downgraded
18 Dec 2023

Financial journalist opinion